Editas Medicine Announces First Quarter 2024 Results and Business Updates Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel for transfusion-dependent beta-thalassemia in mid-2024 and additional updates by year-end 2024 Presenting pre-clinical data at ASGCT on in vivo capabilities to support ...

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins.Participants should a ...

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins.Participants should ...

The market expects Editas Medicine (EDIT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if th ...

CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicines.   Editas ...

Editas Medicine, Inc. (NASDAQ:EDIT) Barclays 26th Annual Global Healthcare Conference March 13, 2024 2:05 PM ET Company Participants Gilmore O'Neil - Chief Executive Officer Erick Lucera - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Gena Wang Good afternoon, everyone, and welcome to Barclays Global Healthcare Conference. My name is Gena Wang. I cover the US mid-cap biotech. It is my great pleasure to introduce our next presenting company, Editas Medicine. With us today we have ...

Editas Medicine, Inc. (NASDAQ:EDIT) Leerink Partners Global Biopharma Conference March 12, 2024 10:40 AM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - Conference Call Participants Mani Foroohar - Leerink Mani Foroohar Good morning, everyone. Welcome back to the 2024 Global Biopharma Conference, Inaugural Miami Conference. So welcome everybody down. I am Mani Foroohar, Senior Analyst Genetic Medicines. And I'm very fortunate to be hosting the team from Editas Medicine. How are you doing? Gilm ...

With Citigroup analyst Samantha Semenkow calling on Feb. 29 for shares of Editas Medicine (EDIT -0.66%) to rise from their current price near $10 to reach $16 -- an increase of 45% over her prior estimate -- there's a clear consensus about the stock forming on Wall Street. Based on Semenkow's price target, which is effectively the same as the consensus average price target across analysts following the stock, Editas Medicine is looking at a 70% bump.It could happen. Here's why.This company just got a huge b ...

Editas Medicine, Inc. (NASDAQ:EDIT) TD Cowen 44th Annual Healthcare Conference March 4, 2024 12:50 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good afternoon and welcome once again to TD Cowen’s 44th Annual Healthcare Conference. I'm Phil Nadeau, one of Cowen’s biotech analysts, and it's my pleasure to moderate a fireside chat with Editas. We have with us today, Gilmore O'Neill, CEO and Erick Lucera, CFO. Hand it over ...

Although equities have performed pretty well in the past three years, many somewhat speculative and unprofitable stocks have struggled as investors have turned their attention away from such corporations. That's the case with Editas Medicine (EDIT -2.47%), a clinical-stage gene editing-focused biotech company.However, many analysts on Wall Street have high hopes for the stock. Editas Medicine's average price target of $15.64 implies an upside of about 55% over its stock price of $10.06 (as of writing). Can ...